Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial.
Mizuno M, Ito K, Nakai H, Kato H, Kamiura S, Ushijima K, Nagao S, Takano H, Okadome M, Takekuma M, Tokunaga H, Nagase S, Aoki D, Coleman RL, Nishimura Y, Ratajczak CK, Hashiba H, Xiong H, Katsumata N, Enomoto T, Okamoto A. Mizuno M, et al. Among authors: ushijima k. Int J Clin Oncol. 2023 Jan;28(1):163-174. doi: 10.1007/s10147-022-02258-x. Epub 2022 Dec 19. Int J Clin Oncol. 2023. PMID: 36534262 Free PMC article. Clinical Trial.
Mutational analysis of the estrogen receptor-alpha gene in familial ovarian cancer.
Wu HJ, Sekine M, Kashima K, Hirai Y, Hatae M, Kobayashi I, Obata K, Enomoto T, Umesaki N, Ushijima K, Tanaka K; Japanese Familial Ovarian Cancer Study Group. Wu HJ, et al. Among authors: ushijima k. J Obstet Gynaecol Res. 2005 Oct;31(5):375-83. doi: 10.1111/j.1447-0756.2005.00305.x. J Obstet Gynaecol Res. 2005. PMID: 16176503
Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
Amikura T, Sekine M, Hirai Y, Fujimoto S, Hatae M, Kobayashi I, Fujii T, Nagata I, Ushijima K, Obata K, Suzuki M, Yoshinaga M, Umesaki N, Satoh S, Enomoto T, Motoyama S, Nishino K, Haino K, Tanaka K; Japanese Familial Ovarian Cancer Study Group. Amikura T, et al. Among authors: ushijima k. Gynecol Oncol. 2006 Feb;100(2):365-71. doi: 10.1016/j.ygyno.2005.09.010. Epub 2005 Dec 9. Gynecol Oncol. 2006. PMID: 16337994
High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, Saito T, Itamochi H, Takano M, Miyagi E, Sudo T, Ushijima K, Iwase H, Seki H, Terao Y, Enomoto T, Mikami M, Akazawa K, Tsuda H, Moriya T, Tajima A, Inoue I, Tanaka K; Japanese Serous Ovarian Cancer Study Group. Yoshihara K, et al. Among authors: ushijima k. Clin Cancer Res. 2012 Mar 1;18(5):1374-85. doi: 10.1158/1078-0432.CCR-11-2725. Epub 2012 Jan 12. Clin Cancer Res. 2012. PMID: 22241791
Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species.
Mizuno T, Suzuki N, Makino H, Furui T, Morii E, Aoki H, Kunisada T, Yano M, Kuji S, Hirashima Y, Arakawa A, Nishio S, Ushijima K, Ito K, Itani Y, Morishige K. Mizuno T, et al. Among authors: ushijima k. Gynecol Oncol. 2015 May;137(2):299-305. doi: 10.1016/j.ygyno.2014.12.005. Epub 2014 Dec 23. Gynecol Oncol. 2015. PMID: 25541259
499 results